PD-1/PD-L1

Home Apoptosis -Immunology & Inflammation -Cell Cycle PD-1/PD-L1

Isoform-selective Products

PD-1/PD-L1 Products

  • All (59)
  • PD-1/PD-L1 Inhibitors (12)
  • PD-1/PD-L1 Antibodies (45)
  • New PD-1/PD-L1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
A2002 Nivolumab (anti-PD-1) Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
Nat Cancer, 2025, 10.1038/s43018-025-00948-9
J Nanobiotechnology, 2025, 23(1):411
MedComm (2020), 2025, 6(8):e70223
Verified customer review of Nivolumab (anti-PD-1)
A2004 Atezolizumab (anti-PD-L1) Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Nat Commun, 2025, 16(1):2374
Nat Commun, 2025, 16(1):4128
J Nanobiotechnology, 2025, 23(1):411
Verified customer review of Atezolizumab (anti-PD-L1)
A2005 Pembrolizumab (anti-PD-1) Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Mol Cancer, 2025, 24(1):80
Nat Commun, 2025, 16(1):2374
J Clin Invest, 2025, e181464
S7912 BMS202 BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
Front Immunol, 2025, 16:1529710
Front Oncol, 2025, 15:1572040
Sci Rep, 2025, 15(1):26918
A2013 Durvalumab (anti-PD-L1) Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
Nature, 2025, 10.1038/s41586-025-09203-8
Sci Rep, 2025, 15(1):16739
bioRxiv, 2025, 2025.03.14.643359
Verified customer review of Durvalumab (anti-PD-L1)
S7911 BMS-1 BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.
Theranostics, 2025, 15(9):3924-3942
J Med Chem, 2024, 67(5):4036-4062
PLoS Comput Biol, 2024, 20(11):e1012284
S8158 PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM
ACS Appl Mater Interfaces, 2024, 16(18):22839-49
J Med Chem, 2024, 67(5):4036-4062
Front Oncol, 2024, 14:1536406
S8275 Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
Nat Commun, 2024, 15(1):9755
Nat Commun, 2024, 15(1):9755
J Clin Invest, 2024, 134(16)e168393
S8859 BMS-1166 BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.
Int J Mol Sci, 2025, 26(14)6876
iScience, 2024, 27(7):110243
Life Sci Alliance, 2024, 10.26508/lsa.202302461
S8549 AUNP-12 AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
Acta Pharm Sin B, 2024, 14(1):350-364
Carcinogenesis, 2022, bgac043
Molecules, 2019, 24(15)
A2015 Avelumab (anti-PD-L1) Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
J Biol Chem, 2024, S0021-9258(24)01826-X
Viruses, 2021, 13(10)2017
Verified customer review of Avelumab (anti-PD-L1)
A2115 Anti-mouse PD-L1 (B7-H1)-InVivo Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
Mol Cell, 2025, 85(13):2517-2534.e6
J Immunother Cancer, 2025, 13(9)e011766
Verified customer review of Anti-mouse PD-L1 (B7-H1)-InVivo
S0094 SR 0987 SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.
Evid Based Complement Alternat Med, 2022, 2022:8315503.
A2017 Spartalizumab (anti-PD-1) Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.
Elife, 2020, 9
F2380 VISTA Antibody [G23H7]
E1322 GS-4224 GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions.
A2381 Serplulimab (Anti-PDCD1 / PD-1 / CD279) Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD.
A2835 Dostarlimab (Anti-PDCD1 / PD-1 / CD279) Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1  programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD.
A2165 Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.
Sci Adv, 2025, 11(5):eadt3044
A2156 Anti-human PD-L1 (B7-H1)-InVivo Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily.
S8473 CA-170 (AUPM-170) CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy.
A2858 Finotonlimab (Anti-PDCD1 / PD-1 / CD279) Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD.
A2022 Cemiplimab (anti-PD-1) Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
Life Sci Alliance, 2024, 7(3)e202302368
A2613 Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD.
A2882 Geptanolimab (Anti-PDCD1 / PD-1 / CD279) Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD.
A2913 Iparomlimab (Anti-PDCD1 / PD-1 / CD279) Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD.
A2122 Anti-mouse PD-1 (CD279)-InVivo Anti-mouse PD-1 (CD279)-InVivo(Clone:RMP1-14) reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.
Signal Transduct Target Ther, 2025, 10(1):82
Signal Transduct Target Ther, 2025, 10(1):88
ACS Nano, 2025, 19(14):13889-13905
Verified customer review of Anti-mouse PD-1 (CD279)-InVivo
A2923 Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
A2956 Nofazinlimab (Anti-PDCD1 / PD-1 / CD279) Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD.
F3016New PD-1 (Intracellular Domain) Antibody [G6H24]
A2171New Anti-mouse PD-L1 (B7-H1) (10F.2H11)-InVivo Anti-mouse PD-L1 (B7-H1) (10F.2H11)-InVivo reacts with mouse PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. The 10F.2H11 antibody has been shown to sterically and functionally block PD-L1/CD80 (B7-1) interactions and does not block PD-L1/PD-1 interactions.
A4002New Cadonilimab (Anti-PD-1 & CTLA-4) Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.
A4003New Pm8002 (Anti-PD-L1 & VEGF) Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.
A2998 Opucolimab (Anti-B7-H1 / PD-L1 / CD274) Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD.
A4005New Erfonrilimab (Anti-CTLA4 & PD-L1) Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to prior platinum-based chemotherapy. MW: 107.44 KD.
S9610 BMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
A4009New Rilvegostomig (Anti-PD-1 & TIGIT) Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06.
E3151 Sanguisorbae Radix Extract Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects.
A4011New Hb0025 (Anti-PD-L1 & VEGF) Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.
A4012New Tqb2858 (Anti-PD-L1 & TGF-β) Tqb2858 is a bifunctional fusion protein consisting of a monoclonal antibody targeting programmed death ligand 1 (PD-L1) fused with the extracellular domain of the transforming growth factor beta (TGF-β) receptor. It simultaneously neutralizes TGF-β on tumor cells and inhibits PD-L1 activity, exhibiting potential antineoplastic and immune checkpoint-modulating effects. MW: 178.22 KD.
A2035 Sintilimab (anti-PD-1) Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
J Immunother Cancer, 2024, 12(9)e009603
S9863 INCB086550 INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
In Vivo, 2025, 39(1):80-95
A4023New Inbrx-105 (Anti-4-1BB & PD-L1) Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo. MW: 101.9 KD.
A2775 Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD.
A2778 Garivulimab (Anti-B7-H1 / PD-L1 / CD274) Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD.
A2780 Manelimab (Anti-B7-H1 / PD-L1 / CD274) Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD.
A4044New Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.
A2781 Pacmilimab (Anti-B7-H1 / PD-L1 / CD274) Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD.
A2782 Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD.
A2783 Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD.
A4051New Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
A4053New Reozalimab(Ibi318) (Anti-PD-1 & PD-L1) Reozalimab(Ibi318) is a first-in-class recombinant IgG1 bispecific antibody that targets both PD-1 and PD-L1, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It fully blocks the PD-1 pathway, disrupts PD-L1/CD80 interactions, and enhances T cell activation for improved tumor cell killing. M.W 143.84 kDa
A4054New Ivonescimab (Anti-PD-1 & VEGF) Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa
A4055New Acasunlimab (Anti-4-1BB & PD-L1) Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa
A4060New Emb-02 (Anti-LAG-3 & PD-1) Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa
A2016 Camrelizumab (anti-PD-1) Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.
Front Immunol, 2025, 16:1612318
Life Sci Alliance, 2024, 7(3)e202302368
A4066New Vudalimab (Anti-CTLA4 & PD-1) Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa
A4068New Lomvastomig (Anti-PD-1 & TIM-3) Lomvastomig is a bispecific antibody targeting both PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune responses. It is designed to treat cancers by promoting T-cell activation and overcoming immune suppression. M.W 145.34 kDa
A2811 Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.
S7912 BMS202 BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
Front Immunol, 2025, 16:1529710
Front Oncol, 2025, 15:1572040
Sci Rep, 2025, 15(1):26918
S7911 BMS-1 BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.
Theranostics, 2025, 15(9):3924-3942
J Med Chem, 2024, 67(5):4036-4062
PLoS Comput Biol, 2024, 20(11):e1012284
S8158 PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM
ACS Appl Mater Interfaces, 2024, 16(18):22839-49
J Med Chem, 2024, 67(5):4036-4062
Front Oncol, 2024, 14:1536406
S8275 Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
Nat Commun, 2024, 15(1):9755
Nat Commun, 2024, 15(1):9755
J Clin Invest, 2024, 134(16)e168393
S8859 BMS-1166 BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.
Int J Mol Sci, 2025, 26(14)6876
iScience, 2024, 27(7):110243
Life Sci Alliance, 2024, 10.26508/lsa.202302461
S8549 AUNP-12 AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
Acta Pharm Sin B, 2024, 14(1):350-364
Carcinogenesis, 2022, bgac043
Molecules, 2019, 24(15)
S0094 SR 0987 SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. SR 0987 represses PD-1, produces IL17 and is potential for the treatment of cancer.
Evid Based Complement Alternat Med, 2022, 2022:8315503.
E1322 GS-4224 GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions.
S8473 CA-170 (AUPM-170) CA-170 (AUPM-170, PD-1-IN-1 ) is potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). CA-170 exhibits anti-tumor efficacy.
S9610 BMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
E3151 Sanguisorbae Radix Extract Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects.
S9863 INCB086550 INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
In Vivo, 2025, 39(1):80-95
A2002 Nivolumab (anti-PD-1) Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
Nat Cancer, 2025, 10.1038/s43018-025-00948-9
J Nanobiotechnology, 2025, 23(1):411
MedComm (2020), 2025, 6(8):e70223
 Verified customer review of Nivolumab (anti-PD-1)
A2004 Atezolizumab (anti-PD-L1) Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Nat Commun, 2025, 16(1):2374
Nat Commun, 2025, 16(1):4128
J Nanobiotechnology, 2025, 23(1):411
 Verified customer review of Atezolizumab (anti-PD-L1)
A2005 Pembrolizumab (anti-PD-1) Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Mol Cancer, 2025, 24(1):80
Nat Commun, 2025, 16(1):2374
J Clin Invest, 2025, e181464
A2013 Durvalumab (anti-PD-L1) Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
Nature, 2025, 10.1038/s41586-025-09203-8
Sci Rep, 2025, 15(1):16739
bioRxiv, 2025, 2025.03.14.643359
 Verified customer review of Durvalumab (anti-PD-L1)
A2015 Avelumab (anti-PD-L1) Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
J Biol Chem, 2024, S0021-9258(24)01826-X
Viruses, 2021, 13(10)2017
 Verified customer review of Avelumab (anti-PD-L1)
A2115 Anti-mouse PD-L1 (B7-H1)-InVivo Anti-mouse PD-L1 (B7-H1)-InVivo (Clone:10F.9G2) monoclonal antibody reacts with mouse PD-L1 (also known as B7-H1, CD274). The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
Mol Cell, 2025, 85(13):2517-2534.e6
J Immunother Cancer, 2025, 13(9)e011766
 Verified customer review of Anti-mouse PD-L1 (B7-H1)-InVivo
A2017 Spartalizumab (anti-PD-1) Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1, MW: 145.8 KD.
Elife, 2020, 9
A2381 Serplulimab (Anti-PDCD1 / PD-1 / CD279) Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD.
A2835 Dostarlimab (Anti-PDCD1 / PD-1 / CD279) Dostarlimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 ((PD-1  programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.18 KD.
A2165 Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo Anti-mouse PD-1 (CD279)(29F.1A12)-InVivo reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.
Sci Adv, 2025, 11(5):eadt3044
A2156 Anti-human PD-L1 (B7-H1)-InVivo Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily.
A2858 Finotonlimab (Anti-PDCD1 / PD-1 / CD279) Finotonlimab (Anti-PDCD1 / PD-1 / CD279) is a recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.38 KD.
A2022 Cemiplimab (anti-PD-1) Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
Life Sci Alliance, 2024, 7(3)e202302368
A2613 Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) Anti-B7-H1 / PD-L1 / CD274 (MDX-1105) is a fully humanized monoclonal antibody targeting B7-H1. It is used in research of advanced melanoma, non-small cell lung carcinoma, renal cell carcinoma, and ovarian cancer. MW :150 KD.
A2882 Geptanolimab (Anti-PDCD1 / PD-1 / CD279) Geptanolimab (Anti-PDCD1 / PD-1 / CD279) is an immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PD1, PDCD1, CD279) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.4 KD.
A2913 Iparomlimab (Anti-PDCD1 / PD-1 / CD279) Iparomlimab (Anti-PDCD1 / PD-1 / CD279) is a human IgG4κ monoclonal antibody targated against PD-1/CD279/PDCD1. Iparomlimab can be used for oncology research. MW: 144.18 KD.
A2122 Anti-mouse PD-1 (CD279)-InVivo Anti-mouse PD-1 (CD279)-InVivo(Clone:RMP1-14) reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdcd1 gene that belongs to the CD28 family of the Ig superfamily.
Signal Transduct Target Ther, 2025, 10(1):82
Signal Transduct Target Ther, 2025, 10(1):88
ACS Nano, 2025, 19(14):13889-13905
 Verified customer review of Anti-mouse PD-1 (CD279)-InVivo
A2923 Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD.
A2956 Nofazinlimab (Anti-PDCD1 / PD-1 / CD279) Nofazinlimab (anti-PDCD1/ PD-1 / CD279) is a humanised IgG4 monoclonal antibody targeting PD-1. Nofazinlimab has the potential to be used in unresectable hepatocellular carcinoma (uHCC) research. MW: 145.08 KD.
A2171New Anti-mouse PD-L1 (B7-H1) (10F.2H11)-InVivo Anti-mouse PD-L1 (B7-H1) (10F.2H11)-InVivo reacts with mouse PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. The 10F.2H11 antibody has been shown to sterically and functionally block PD-L1/CD80 (B7-1) interactions and does not block PD-L1/PD-1 interactions.
A4002New Cadonilimab (Anti-PD-1 & CTLA-4) Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.
A4003New Pm8002 (Anti-PD-L1 & VEGF) Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.
A2998 Opucolimab (Anti-B7-H1 / PD-L1 / CD274) Opucolimab (Anti-B7-H1 / PD-L1 / CD274) is a recombinant human monoclonal antibody targeting PD-L1. It can be used for the research of advanced solid tumors. MW :144.68 KD.
A4005New Erfonrilimab (Anti-CTLA4 & PD-L1) Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to prior platinum-based chemotherapy. MW: 107.44 KD.
A4009New Rilvegostomig (Anti-PD-1 & TIGIT) Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06.
A4011New Hb0025 (Anti-PD-L1 & VEGF) Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.
A4012New Tqb2858 (Anti-PD-L1 & TGF-β) Tqb2858 is a bifunctional fusion protein consisting of a monoclonal antibody targeting programmed death ligand 1 (PD-L1) fused with the extracellular domain of the transforming growth factor beta (TGF-β) receptor. It simultaneously neutralizes TGF-β on tumor cells and inhibits PD-L1 activity, exhibiting potential antineoplastic and immune checkpoint-modulating effects. MW: 178.22 KD.
A2035 Sintilimab (anti-PD-1) Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
J Immunother Cancer, 2024, 12(9)e009603
A4023New Inbrx-105 (Anti-4-1BB & PD-L1) Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo. MW: 101.9 KD.
A2775 Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, cluster of differentiation 274, CD274) with promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). MW: 145.8 kD.
A2778 Garivulimab (Anti-B7-H1 / PD-L1 / CD274) Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD.
A2780 Manelimab (Anti-B7-H1 / PD-L1 / CD274) Manelimab (Anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 143.68 kD.
A4044New Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.
A2781 Pacmilimab (Anti-B7-H1 / PD-L1 / CD274) Pacmilimab (anti-B7-H1 / PD-L1 / CD274) is a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. MW: 152.6 kD.
A2782 Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD.
A2783 Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) Sugemalimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small-cell lung cancer research. MW: 143.36 kD.
A4051New Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
A4053New Reozalimab(Ibi318) (Anti-PD-1 & PD-L1) Reozalimab(Ibi318) is a first-in-class recombinant IgG1 bispecific antibody that targets both PD-1 and PD-L1, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It fully blocks the PD-1 pathway, disrupts PD-L1/CD80 interactions, and enhances T cell activation for improved tumor cell killing. M.W 143.84 kDa
A4054New Ivonescimab (Anti-PD-1 & VEGF) Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa
A4055New Acasunlimab (Anti-4-1BB & PD-L1) Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa
A4060New Emb-02 (Anti-LAG-3 & PD-1) Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa
A2016 Camrelizumab (anti-PD-1) Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities, MW: 146.3 KD.
Front Immunol, 2025, 16:1612318
Life Sci Alliance, 2024, 7(3)e202302368
A4066New Vudalimab (Anti-CTLA4 & PD-1) Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa
A4068New Lomvastomig (Anti-PD-1 & TIM-3) Lomvastomig is a bispecific antibody targeting both PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune responses. It is designed to treat cancers by promoting T-cell activation and overcoming immune suppression. M.W 145.34 kDa
A2811 Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) Cosibelimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 144.64 KD.
F3016New PD-1 (Intracellular Domain) Antibody [G6H24]
A2171New Anti-mouse PD-L1 (B7-H1) (10F.2H11)-InVivo Anti-mouse PD-L1 (B7-H1) (10F.2H11)-InVivo reacts with mouse PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. The 10F.2H11 antibody has been shown to sterically and functionally block PD-L1/CD80 (B7-1) interactions and does not block PD-L1/PD-1 interactions.
A4002New Cadonilimab (Anti-PD-1 & CTLA-4) Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.
A4003New Pm8002 (Anti-PD-L1 & VEGF) Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.
A4005New Erfonrilimab (Anti-CTLA4 & PD-L1) Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to prior platinum-based chemotherapy. MW: 107.44 KD.
A4009New Rilvegostomig (Anti-PD-1 & TIGIT) Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06.
A4011New Hb0025 (Anti-PD-L1 & VEGF) Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.
A4012New Tqb2858 (Anti-PD-L1 & TGF-β) Tqb2858 is a bifunctional fusion protein consisting of a monoclonal antibody targeting programmed death ligand 1 (PD-L1) fused with the extracellular domain of the transforming growth factor beta (TGF-β) receptor. It simultaneously neutralizes TGF-β on tumor cells and inhibits PD-L1 activity, exhibiting potential antineoplastic and immune checkpoint-modulating effects. MW: 178.22 KD.
A4023New Inbrx-105 (Anti-4-1BB & PD-L1) Inbrx-105 is a recombinant, humanized bispecific antibody targeting programmed death-ligand 1 (PD-L1) and 4-1BB (CD137), with potential checkpoint inhibitory, immunostimulating, and antineoplastic activities. By binding to 4-1BB on activated T lymphocytes and PD-L1 on tumor cells, INBRX-105 enhances T-cell co-stimulation and inhibits PD-L1-mediated T-cell inhibition, potentially leading to reduced tumor growth. INBRX-105 exhibits antitumor efficacy and increased T-cell frequency in patients with solid tumors and in in-vivo. MW: 101.9 KD.
A4044New Tobemstomig (Anti-LAG-3 & PD-1) Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T-cell activation. By blocking these immune checkpoints, it promotes a cytotoxic T-cell response and exhibits potential antitumor effects. M.W 145.24 kDa.
A4051New Volrustomig (Anti-CTLA4 & PD-1) Volrustomig is an engineered fragment crystallizable (Fc) domain, monovalent bispecific IgG1 monoclonal antibody targeting PD-1 and CTLA-4, key immune checkpoint receptors. It enhances T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. M.W 146.77 kDa
A4053New Reozalimab(Ibi318) (Anti-PD-1 & PD-L1) Reozalimab(Ibi318) is a first-in-class recombinant IgG1 bispecific antibody that targets both PD-1 and PD-L1, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It fully blocks the PD-1 pathway, disrupts PD-L1/CD80 interactions, and enhances T cell activation for improved tumor cell killing. M.W 143.84 kDa
A4054New Ivonescimab (Anti-PD-1 & VEGF) Ivonescimab is a first-in-class humanized tetravalent bispecific antibody targeting PD-1 and VEGF-A, with immune checkpoint inhibitory, anti-angiogenic, and antineoplastic activities. It is being developed for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors, including breast, liver, and gastric cancers. M.W 201.12 kDa
A4055New Acasunlimab (Anti-4-1BB & PD-L1) Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa
A4060New Emb-02 (Anti-LAG-3 & PD-1) Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa
A4066New Vudalimab (Anti-CTLA4 & PD-1) Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa
A4068New Lomvastomig (Anti-PD-1 & TIM-3) Lomvastomig is a bispecific antibody targeting both PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune responses. It is designed to treat cancers by promoting T-cell activation and overcoming immune suppression. M.W 145.34 kDa

Choose Selective PD-1/PD-L1 Inhibitors